溃疡性结肠炎的治疗选择

Choosing Therapies in Ulcerative Colitis.

作者信息

Das Ronit, Steinhart A Hillary

机构信息

Gastroenterology / IBD - Mount Sinai Hospital IBD Centre, Toronto, Canada.

Department of Medicine, University of Toronto, Toronto, Canada.

出版信息

J Can Assoc Gastroenterol. 2023 Sep 4;7(1):9-21. doi: 10.1093/jcag/gwad025. eCollection 2024 Feb.

Abstract

Those managing ulcerative colitis (UC) must be aware of new treatments. Mesalamine (5-ASA) is the first treatment for mild UC. Steroids have been the first therapy for patients with more severe UC but these are not effective or safe long term. This means that other medicines are needed. Newer advanced therapies are now frequently used. There are several types of advanced therapies. These are the anti-TNF, anti-integrin and anti-IL12/23 agents as well as the JAK inhibitors and sphingosine1-phosphate receptor modulators. All of these are effective in treating UC. Choosing among treatments is complicated. There are multiple factors to think about when choosing a treatment for UC. Without research studies that directly compare the different treatments, the use of any one treatment should be based on effectiveness and safety. Other considerations include specific disease features, patient factors and the preference of patients.

摘要

溃疡性结肠炎(UC)的治疗人员必须了解新的治疗方法。美沙拉嗪(5-ASA)是轻度UC的首选治疗药物。类固醇一直是重度UC患者的一线治疗药物,但长期使用这些药物既无效也不安全。这意味着需要其他药物。现在新型先进疗法经常被使用。先进疗法有几种类型。这些包括抗TNF、抗整合素和抗IL12/23药物,以及JAK抑制剂和鞘氨醇1-磷酸受体调节剂。所有这些药物在治疗UC方面都很有效。在各种治疗方法中进行选择很复杂。为UC选择治疗方法时需要考虑多个因素。由于缺乏直接比较不同治疗方法的研究,任何一种治疗方法的使用都应基于有效性和安全性。其他需要考虑的因素包括特定的疾病特征、患者因素以及患者的偏好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65df/10836994/3cef74a00714/gwad025_fig1.jpg

本文引用的文献

[2]

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索